Abstract
Background: Anti-JCV antibody titers (JCVAbTs) are currently proposed as predictors for development of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS) who are treated with disease modifying drugs (DMDs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
